The present invention relates to preparation and use of nanocellulose fibrils or crystals such as disintegrated bacterial nanocellulose, tunicate-derived nanocellulose, or plant-derived nanocellulose, together with carbon nanotubes, as a biocompatible and conductive ink for 3D printing of electrically conductive patterns. Biocompatible conductive bioinks described in this invention were printed in the form of connected lines onto wet or dried nanocellulose films, bacterial cellulose membrane, or tunicate decellularized tissue. The devices were biocompatible and showed excellent mechanical properties and good electrical conductivity through printed lines (3.8.Math.10.sup.−1 S cm.sup.−1). Such scaffolds were used to culture neural cells. Neural cells attached selectively on the printed pattern and formed connective networks. The devices prepared by this invention are suited as bioassays to screen drugs against neurodegenerative diseases such as Alzheimer's and Parkinson's, study brain function, and/or be used to link the human brain with electronic and/or communication devices. They can also be implanted to replace neural tissue or stimulate guiding of neural cells. They can also be used to stimulate the heart by using electrical signaling or to repair myocardial infarction and/or damage related thereto.

There are disclosed implantable medical devices and apparatus for treating implantable medical devices during production, so as to cause the implantable medical devices to have abluminal surfaces and luminal surfaces with different functional characteristics and in particular surface energies. The luminal surfaces of the medical device are preferably coated with carbon, so as to have a low surface energy, which reduces the risk of thrombi forming when implanted into a patient's vessels. The abluminal surfaces are treated so as to have a high surface energy, such that a therapeutic, preferably bioactive, material, such as a drug, can adhere to the abluminal surfaces and preferably without any need for a containment layer such as polymer or other matrix material. Once the therapeutic material has been delivered into the tissue wall, the stent can remain within the patient's vessel without leaving any delivery artefacts, as occurs with some prior art drug eluting medical devices.

The application discloses an implantable device, comprising a galvanic redox system formed on a body substrate of the implantable device. The implantable device has a non-zero surface potential when it is deployed. The galvanic redox system comprises a first metal site and a second metal site, the first metal site comprising a first metal having a first metal electrode potential (FMEP) and the second metal site comprising a second metal having a second metal electrode potential (SMEP), which FMEP being lower than SMEP and SMEP being substantially different such that the implantable device is galvanized when it is deployed. Methods of making and using the implantabe device are also disclosed.

The application discloses an implantable device, comprising a galvanic redox system formed on a body substrate of the implantable device. The implantable device has a non-zero surface potential when it is deployed. The galvanic redox system comprises a first metal site and a second metal site, the first metal site comprising a first metal having a first metal electrode potential (FMEP) and the second metal site comprising a second metal having a second metal electrode potential (SMEP), which FMEP being lower than SMEP and SMEP being substantially different such that the implantable device is galvanized when it is deployed. Methods of making and using the implantabe device are also disclosed.

A method of making an implant having a porous portion is disclosed. The method comprises the following steps: obtaining an artificial foam containing porous portion; scanning the artificial foam to obtain a digital porous model; editing the digital porous model; assembling the digital porous model to form a digital porous block; editing the digital porous block to obtain a digital implant model; forming the implant by printing the digital implant model through a 3D printer. An implant and a method of calculating porosity a porosity of a porous material are also disclosed.

The present invention relates to a composition for preparing a decellularized scaffold, including nano graphene oxide. The present inventors crosslinked nano graphene oxide to a decellularized liver scaffold to strengthen the properties of the scaffold and suppress protease activity of the scaffold, and thus have established an optimum crosslinking condition exhibiting the effects of anti-inflammation and polarization to M2 macrophages. That is, since it is confirmed that nano graphene oxide strengthens the durability of the scaffold so that biodegradation is suppressed and, simultaneously, inflammatory responses that may occur after transplantation are minimized, it is expected that nano graphene oxide can be effectively used in the production and transplantation of clinically applicable artificial organs.

The present invention relates to a composition for preparing a decellularized scaffold, including nano graphene oxide. The present inventors crosslinked nano graphene oxide to a decellularized liver scaffold to strengthen the properties of the scaffold and suppress protease activity of the scaffold, and thus have established an optimum crosslinking condition exhibiting the effects of anti-inflammation and polarization to M2 macrophages. That is, since it is confirmed that nano graphene oxide strengthens the durability of the scaffold so that biodegradation is suppressed and, simultaneously, inflammatory responses that may occur after transplantation are minimized, it is expected that nano graphene oxide can be effectively used in the production and transplantation of clinically applicable artificial organs.

The present invention relates to a medical product, comprising an antibacterial hard material coating, which is applied to a main body and which comprises biocide. Said hard material coating includes at least one inner layer and one outer layer, wherein the biocide concentration in the outer layer is substantially constant and greater than the biocide concentration in the inner layer and the biocide concentration in the inner layer is greater than or equal to 0.2 at %.

An antibacterial device is disclosed that includes a substrate and an antibacterial coating or antibacterial surface being provided on at least a part of the substrate's surface. The antibacterial coating or surface includes Angstrom scale flakes, where the Angstrom scale flakes are arranged in a standing position on the substrate surface and are attached to the substrate surface via edge sides thereof. The Angstrom scale flakes can, for example, be graphene flakes, or graphite flakes having a thickness of a few atom layers. It has been found that such standing flakes are efficient in killing prokaryotic cells but do not harm eukaryotic cells.

An antibacterial device is disclosed that includes a substrate and an antibacterial coating or antibacterial surface being provided on at least a part of the substrate's surface. The antibacterial coating or surface includes Angstrom scale flakes, where the Angstrom scale flakes are arranged in a standing position on the substrate surface and are attached to the substrate surface via edge sides thereof. The Angstrom scale flakes can, for example, be graphene flakes, or graphite flakes having a thickness of a few atom layers. It has been found that such standing flakes are efficient in killing prokaryotic cells but do not harm eukaryotic cells.